1. A Sound Rationale Needed for Phase III HIV- 1 VaccineTrials.
- Author
-
Burton, Dennis R., Desrosiers, Ronald C., Doms, Robert W., Feinberg, Mark B., Gallo, Robert C., Hahn, Beatrice, Hoxie, James A., Hunter, Eric, Korber, Bette, Landay, Alan, Lederman, Michael M., Lieberman, Judy, McCune, Joseph M., Moore, John P., Nathanson, Neal, Picker, Louis, Richman, Douglas, Rinaldo, Charles, Stevenson, Mario, and Watkins, David I.
- Subjects
- *
AIDS vaccines , *HIV , *CELLULAR immunity , *VACCINES , *VIROLOGY , *EXPERIMENTAL medicine , *EXPERIMENTAL immunology - Abstract
The need for a human immunodeficiency virus-1 (HIV-1) vaccine HN1 is unquestioned, and the authors strongly support its development as the highest AIDS research priority. The authors express their concern about the wisdom of the U.S. government's sponsoring a recently initiated phase III trial HN2 in Thailand of a vaccine made from the live-replicating canarypox vector ALVAC HN3 with a boost of monomeric gp120. The original aim of this trial was to determine whether a combination of immunogens designed to induce cellular immunity and humoral immunity HN5 could prevent infection and/or lead to the immune control of HIV-1 replication postinfection. The authors' opinion is that the overall approval process lacked input from independent immunologists and virologists who could have judged whether the trial was scientifically meritorious.
- Published
- 2004
- Full Text
- View/download PDF